{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:15:45Z","timestamp":1790349345960,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T00:00:00Z","timestamp":1456876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s40256-016-0166-3","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T06:03:51Z","timestamp":1456898631000},"page":"141-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Alirocumab: A Review in Hypercholesterolemia"],"prefix":"10.1007","volume":"16","author":[{"given":"Sarah L.","family":"Greig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,2]]},"reference":[{"issue":"8","key":"166_CR1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/phar.1621","volume":"35","author":"AN Okere","year":"2015","unstructured":"Okere AN, Serra C. Evaluation of the potential role of alirocumab in the management of hypercholesterolemia in patients with high-risk cardiovascular disease. Pharmacotherapy. 2015;35(8):771\u20139.","journal-title":"Pharmacotherapy."},{"issue":"16","key":"166_CR2","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","volume":"62","author":"D Urban","year":"2013","unstructured":"Urban D, P\u00f6ss J, B\u00f6hm M, et al. Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62(16):1401\u20138.","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"166_CR3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report. J Clin Lipidol. 2015;9(2):129\u201369.","journal-title":"J Clin Lipidol."},{"issue":"14","key":"166_CR4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"\u017d Reiner","year":"2011","unstructured":"Reiner \u017d, Catapano AL, De Backer G, et al. ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769\u2013818.","journal-title":"Eur Heart J."},{"key":"166_CR5","doi-asserted-by":"crossref","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934.","DOI":"10.1016\/j.jacc.2013.11.002"},{"issue":"36","key":"166_CR6","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/eurheartj\/ehv174","volume":"36","author":"YJ Shimada","year":"2015","unstructured":"Shimada YJ, Cannon CP. PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36(36):2415\u201324.","journal-title":"Eur Heart J."},{"key":"166_CR7","doi-asserted-by":"crossref","unstructured":"Stein EA, Swergold GD. Potential of proprotein convertase subtilisin\/kexin type 9 based therapeutics. Curr Atheroscler Rep. 2013;15(3):[article no. 310].","DOI":"10.1007\/s11883-013-0310-3"},{"issue":"1","key":"166_CR8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","volume":"228","author":"AL Catapano","year":"2013","unstructured":"Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228(1):18\u201328.","journal-title":"Atherosclerosis."},{"key":"166_CR9","unstructured":"Sanofi-Aventis Groupe. Praluent solution for injection: EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 11 Feb 2016."},{"key":"166_CR10","unstructured":"Regeneron Pharmaceuticals Inc, Sanofi-Aventis US LLC. Praluent (alirocumab) injection, for subcutaneous use: US prescribing information. 2015. http:\/\/www.fda.gov . Accessed 11 Feb 2016."},{"issue":"10","key":"166_CR11","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1194\/jlr.M051326","volume":"55","author":"S K\u00fchnast","year":"2014","unstructured":"K\u00fchnast S, van der Hoorn JWA, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55(10):2103\u201312.","journal-title":"J Lipid Res."},{"issue":"12","key":"166_CR12","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","volume":"366","author":"EA Stein","year":"2012","unstructured":"Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108\u201318.","journal-title":"N Engl J Med."},{"issue":"6","key":"166_CR13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","volume":"32","author":"C Lunven","year":"2014","unstructured":"Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014;32(6):297\u2013301.","journal-title":"Cardiovasc Ther."},{"issue":"16","key":"166_CR14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med."},{"issue":"20","key":"166_CR15","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","volume":"367","author":"EM Roth","year":"2012","unstructured":"Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891\u2013900.","journal-title":"N Engl J Med."},{"issue":"25","key":"166_CR16","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344\u201353.","journal-title":"J Am Coll Cardiol."},{"issue":"9836","key":"166_CR17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29\u201336.","journal-title":"Lancet."},{"key":"166_CR18","unstructured":"Teramoto T, Kobayashi M, Uno K, et al. Efficacy and safety of alirocumab in Japanese patients with hypercholesterolemia on stable statin therapy: first data with the 75\u00a0mg every two weeks dose [abstract no. 13651]. Circulation. 2014;124(21 Suppl 1)."},{"issue":"1","key":"166_CR19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","volume":"176","author":"EM Roth","year":"2014","unstructured":"Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176(1):55\u201361.","journal-title":"Int J Cardiol."},{"key":"166_CR20","doi-asserted-by":"crossref","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906\u201315.e13.","DOI":"10.1016\/j.ahj.2015.03.004"},{"issue":"19","key":"166_CR21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186\u201394.","journal-title":"Eur Heart J."},{"issue":"8","key":"166_CR22","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","volume":"100","author":"H Bays","year":"2015","unstructured":"Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100(8):3140\u20138.","journal-title":"J Clin Endocrinol Metab."},{"key":"166_CR23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","volume":"244","author":"M Farnier","year":"2016","unstructured":"Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138\u201346.","journal-title":"Atherosclerosis."},{"key":"166_CR24","unstructured":"Ginsberg HN, Rader DJ, Raal FJ, et al. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia [abstract no. CS.05 plus slides]. In: 87th Annual Scientific Sessions of the American Heart Association; 2014."},{"issue":"43","key":"166_CR25","first-page":"2996","volume":"36","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996\u20133003.","journal-title":"Eur Heart J."},{"issue":"6","key":"166_CR26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin-re-challenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758\u201369.","journal-title":"J Clin Lipidol."},{"issue":"3","key":"166_CR27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","volume":"28","author":"JJ Kastelein","year":"2014","unstructured":"Kastelein JJ, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014;28(3):281\u20139.","journal-title":"Cardiovasc Drugs Ther."},{"issue":"10","key":"166_CR28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/clc.22327","volume":"37","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Colhoun HM, Bays HE, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40\u00a0mg) or rosuvastatin (10 or 20\u00a0mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014;37(10):597\u2013604.","journal-title":"Clin Cardiol."},{"issue":"1","key":"166_CR29","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.atherosclerosis.2015.04.099","volume":"241","author":"M Farnier","year":"2015","unstructured":"Farnier M, Gaudet D, Valcheva V, et al. Efficacy of alirocumab in heterozygous familial hypercholesterolemia or high CV risk populations: pooled analyses of eight phase 3 trials [abstract no. EAS-0563]. Atherosclerosis. 2015;241(1):e25\u20136.","journal-title":"Atherosclerosis."},{"issue":"Suppl 1","key":"166_CR30","first-page":"1141","volume":"36","author":"M-R Taskinen","year":"2015","unstructured":"Taskinen M-R, Cannon CP, Thompson D, et al. Consistent reductions in atherogenic lipid parameters with the PCSK9 inhibitor alirocumab in patients not receiving background statin [abstract no. P6427]. Eur Heart J. 2015;36(Suppl 1):1141.","journal-title":"Eur Heart J."},{"issue":"3","key":"166_CR31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacl.2015.03.096","volume":"9","author":"HE Bays","year":"2015","unstructured":"Bays HE, Leiter LA, Colhoun HM, et al. Alirocumab treatment effect on non-HDL-C: pooled analyses of 10 phase 3 trials in the ODYSSEY program [abstract no. 183]. J Clin Lipidol. 2015;9(3):471\u20132.","journal-title":"J Clin Lipidol."},{"issue":"Suppl 1","key":"166_CR32","first-page":"1047","volume":"36","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Watts GF, Robinson JG, et al. Sustained treatment effect of alirocumab on Lp(a): pooled analyses from 4,915 patients in ten phase 3 trials in the ODYSSEY program [abstract no. P5980]. Eur Heart J. 2015;36(Suppl 1):1047.","journal-title":"Eur Heart J."},{"key":"166_CR33","unstructured":"Bruckert E, Kereiakes DJ, Koren MJ, et al. Alirocumab leads to similar LDL-C reduction in 4812 patients (from nine phase 3 trials) with and without prior MI\/ischemic stroke [abstract no. 327]. In: 17th International Symposium on Atherosclerosis; 2015."},{"key":"166_CR34","unstructured":"Hovingh K, Ceska R, Louie MJ, et al. Alirocumab treatment effect did not differ between patients with\/without low LDL-C or high triglyceride baseline levels in phase 3 trials [abstract no. 326]. In: 17th International Symposium on Atherosclerosis; 2015."},{"issue":"10 Suppl","key":"166_CR35","doi-asserted-by":"crossref","first-page":"A1363","DOI":"10.1016\/S0735-1097(15)61363-8","volume":"65","author":"PH Jones","year":"2015","unstructured":"Jones PH, Bays H, Chaudhari U, et al. Pooled safety and adverse events in nine randomized, placebo-controlled, phase 2 and 3 clinical trials of alirocumab [abstract no. 914-08]. J Am Coll Cardiol. 2015;65(10 Suppl):A1363.","journal-title":"J Am Coll Cardiol."},{"issue":"10 Suppl","key":"166_CR36","doi-asserted-by":"crossref","first-page":"A1350","DOI":"10.1016\/S0735-1097(15)61350-X","volume":"65","author":"J Robinson","year":"2015","unstructured":"Robinson J, Farnier M, Chaudhari U, et al. Adverse events in patients with low-density lipoprotein cholesterol levels <25 or <15\u00a0mg\/dL on at least two consecutive visits in fourteen randomized, controlled, clinical trials of alirocumab [abstract no. 1164M-05 plus poster]. J Am Coll Cardiol. 2015;65(10 Suppl):A1350.","journal-title":"J Am Coll Cardiol."},{"key":"166_CR37","doi-asserted-by":"crossref","unstructured":"Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(Suppl):S1\u2013122.e1.","DOI":"10.1016\/j.jacl.2015.09.002"},{"issue":"5","key":"166_CR38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682\u20139.","journal-title":"Am Heart J."},{"issue":"8","key":"166_CR39","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","volume":"46","author":"SD Wiviott","year":"2005","unstructured":"Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46(8):1411\u20136.","journal-title":"J Am Coll Cardiol."},{"key":"166_CR40","doi-asserted-by":"crossref","unstructured":"Amgen Europe BV. Repatha solution for injection: EU summary of product characteristics. 2015. http:\/\/ema.europa.eu . Accessed 11 Feb 2016.","DOI":"10.1787\/health_glance_eur-2016-2-en"},{"key":"166_CR41","unstructured":"Amgen Inc. Repatha (evolocumab) injection, for subcutaneous use: US prescribing information. 2015. http:\/\/www.fda.gov . Accessed 11 Feb 2016."},{"key":"166_CR42","unstructured":"Roth EM, Rader DJ, Moriarty PM, et al. Phase 3 randomized trial evaluating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE I [abstract no. 254]. In: 17th International Symposium on Atherosclerosis; 2015."},{"key":"166_CR43","unstructured":"Stroes ES, Guyton JR, Lepor N, et al. Alirocumab in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study [abstract no. 269]. In: 17th International Symposium on Atherosclerosis; 2015."},{"key":"166_CR44","unstructured":"Institute for Clinical and Economic Review. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks: final report. 2015. http:\/\/cepac.icer-review.org . Accessed 11 Feb 2016."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-016-0166-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0166-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T22:25:29Z","timestamp":1654467929000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-016-0166-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["166"],"URL":"https:\/\/doi.org\/10.1007\/s40256-016-0166-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,2]]}}}